R-Zero vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 54)
R-Zero logo

R-Zero

ChallengerHealthcare

Infection Control & Indoor Health Technology

R-Zero combines UV-C disinfection hardware with IoT sensors and AI to reduce pathogen transmission and cut HVAC energy costs 20–40% in healthcare, education, and commercial buildings; raised $58M+.

AI VisibilityBeta
Overall Score
C54
Category Rank
#183 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
54
Perplexity
49
Gemini
54

About

R-Zero is an indoor health and intelligent building platform that integrates UV-C disinfection technology with IoT-connected environmental sensors and AI-driven automation. The company's product suite includes mobile and fixed UV-C disinfection units alongside occupancy and air-quality sensors that feed a building management layer capable of autonomously adjusting HVAC systems to reduce energy consumption by 20–40% without infrastructure changes. Customers include healthcare systems, K–12 schools, universities, and corporate facilities managers seeking to simultaneously reduce infection risk and operating costs.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

54
Overall Score
90
#183
Category Rank
#2
83
AI Consensus
83
stable
Trend
stable
54
ChatGPT
92
49
Perplexity
93
54
Gemini
89
54
Claude
96
49
Grok
95

Key Details

Category
Infection Control & Indoor Health Technology
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.